Investigating targeted radiotherapy for children with neuroblastoma
Research Project 2: Neuroblastoma
This study is looking at how a special treatment called 131I-MIBG works on tumor cells in children with high-risk neuroblastoma, and it aims to find out what makes these tumors respond to the treatment and how it might affect kids in the long run, all to help improve future care for young patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931440 on NIH RePORTER |
What this research studies
This research focuses on understanding how targeted radiopharmaceuticals, specifically 131I-MIBG, affect tumor cells and their environment in children with high-risk neuroblastoma. By analyzing tumor samples and blood from patients, the study aims to identify genetic and biological factors that influence how these tumors respond to treatment. The research will also explore the long-term effects of this therapy on young patients, providing insights that could improve future treatments and patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with high-risk neuroblastoma.
Not a fit: Patients with neuroblastoma who are not classified as high-risk or those outside the age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for neuroblastoma and better management of late effects in pediatric patients.
How similar studies have performed: Previous research has shown promise in using targeted radiopharmaceuticals for treating various cancers, indicating potential success for this approach in neuroblastoma.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Chowdhury, Dipanjan — Dana-Farber Cancer Inst
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.